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Regenerative medicine therapies hold enormous potential for a variety of currently incurable conditions with high unmet clinical
need. Most progress in this ﬁeld to date has been achieved with cell-based regenerative medicine therapies, with over a thousand
clinical trials performed up to 2015. However, lack of adequate safety and efﬁcacy data is currently limiting wider uptake of these
therapies. To facilitate clinical translation, non-invasive in vivo imaging technologies that enable careful evaluation and
characterisation of the administered cells and their effects on host tissues are critically required to evaluate their safety and efﬁcacy
in relevant preclinical models. This article reviews the most common imaging technologies available and how they can be applied
to regenerative medicine research. We cover details of how each technology works, which cell labels are most appropriate for
different applications, and the value of multi-modal imaging approaches to gain a comprehensive understanding of the responses
to cell therapy in vivo.
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INTRODUCTION
Cell-based regenerative medicine therapies (RMTs) and their
translation to clinical application are now a major focus of research
and are likely to play a key role in future clinical practice. Broadly,
cell-based RMTs encompass various cell types, including stem cells,
stromal cells, and macrophages and have the potential to treat
many diseases, including neurodegenerative and musculoskeletal
disorders.1 Many RMTs have shown great promise in preclinical
studies for various diseases, including kidney2 and liver diseases,3
type I diabetes and myocardial infarction4; however, success in the
clinical setting is limited, with only a small panel of fully approved
RMTs available to patients, such as dermal reconstruction, or repair
of orthopaedic defects.5 The slow translation of RMTs from bench
to bedside is primarily due to the lack of convincing data on the
safety of RMTs, in addition to uncertainties on the true efﬁcacy and
mode of action of the cell therapy.6 The importance of acquiring
convincing safety and efﬁcacy data in preclinical models before
applying such therapies in man is underscored by the disastrous
outcomes of bioengineered tracheal transplantation, a procedure
that was applied in man before being shown to be safe or effective
in animals.7 Commercial stem-cell clinics around the world can
now use autologous cellular therapies outside the experimental
clinical trial settings endangering patient’s health.8 A clear example
happened in three patients in the US whom clinically received
intravitreal injections of autologous adipose tissue-derived “stem
cells” and developed severe bilateral visual loss.9
The main concerns regarding translation of cell-based RMTs to
the clinic are:
1. Tumourigenicity—Pluripotent stem cell-based RMTs are a
particular concern due to the propensity of these cells to from
teratomas and/or teratocarcinomas; it is important for the
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tumourigenicity of these cell-based RMTs to be assessed in
animal models before being used in the clinic.
2. Immunogenicity—RMTs consisting of allogeneic cells have
the potential for evoking an immune reaction in the host; this
needs to be managed with respect to the function of the
therapy before the RMT is translated to the clinic.
3. Efﬁcacy—The RMT must be proven to have greater efﬁcacy
compared to standard therapies for treating a particular
disease.
4. Mechanisms of action—It is important to fully understand
why the RMT is having a beneﬁcial effect in order to
understand whether the cells themselves are therapeutic, or
their derived factors.
5. Risk:Beneﬁt ratio—All of the above points need to be
considered with the risk:beneﬁt ratio in mind. For example,
a small risk of tumourigenicity is likely to be more acceptable
if it is being used to treat a life-threatening disease with no
alternative treatment (high beneﬁt), than if the RMT is being
used to treat a condition that is not life-limiting and/or only
provides a modest advantage over current treatments (low
beneﬁt).
Relevant animal models, where available, are essential to gain a
better understanding of both the efﬁcacy and the safety of cell-
based RMTs. Current methods generally rely on histological
analysis of tissues post-mortem.10 This approach requires many
experimental animals to be sacriﬁced at multiple time points in
order to gain a comprehensive insight into in vivo processes
following administration of the RMT. Importantly, it does not allow
researchers to monitor individual animals over the course of their
treatment. This need can be addressed by developing non-
invasive imaging methods that can monitor the response of each
animal longitudinally.11
Preclinical imaging encompasses several different imaging
modalities, some of which are only suitable for imaging small
animals, and others that can be used in large animals and in the
clinic.12 Modalities which can be universally applied include
magnetic resonance imaging (MRI) and nuclear imaging. Other
modalities, such as optical and whole-body optoacoustic imaging,
can only be used in small animals, but are nevertheless invaluable
because they allow the whole-body biodistribution of the cells to
be monitored over the long-term using genetic reporters; this is
not currently possible in the clinical setting.
We aim to provide a review of preclinical imaging with a
particular focus on assessing the safety, efﬁcacy, and mechanisms
of action of RMTs. There are several different imaging modalities
available in preclinical research, but this review will focus on the
four main modalities, which are: optical (ﬂuorescence and
bioluminescence imaging (FLI; BLI)), MRI, nuclear imaging, and
optoacoustic imaging.
PRECLINICAL IMAGING AND CELL LABELLING
Imaging modalities
Optical imaging is a commonly used modality, as it can provide
fast, high-throughput, whole-body imaging13 (see Box 1, Table 1).
Transplanted cells containing ﬂuorescence or (bio)luminescence,
either as a result of directly labelling the cells with probes (see Box
2) or by introducing reporter genes (see Box 3), can be tracked
using optical imaging, thus allowing the monitoring of cell
biodistribution and tumour formation. Disadvantages of optical
imaging include low penetration depth, poor spatial resolution,
and poor quantiﬁcation capabilities.13
MRI provides excellent anatomical information with unlimited
tissue penetration depth14 (see Box 1, Table 1), allowing detailed
structural examination of organs before and after RMT adminis-
tration. Additionally, cells labelled with paramagnetic or super-
paramagnetic agents (see Box 2) or over-expressing magnetic
resonance (MR) reporter genes such as ferritin, tyrosinase, or β-
galactosidase (see Box 3) can be tracked using MRI, although most
MR reporters have been shown to have limited efﬁcacy.15 The
detailed structural information obtained from MR images allows
the biodistribution of labelled cells to be attributed to speciﬁc
organs with far greater accuracy and spatial resolution than with
optical imaging. However, it is difﬁcult to track cells in regions with
inherently variable MRI contrast, such as the lungs, bone, gut, and
spleen.16 Because cell tracking via MR is dependent on the effect
the labelling agent has on water proton signal (T1/T2 relaxation),
the observed contrast is not always easily discriminated from
other pathological processes. For example, labelling with iron
oxides reduces T2/T2
* signal, an effect that is also seen in areas of
haemorrhage or in iron overload diseases such as hemosiderosis.
Unlike iron oxides, gadolinium chelates give a positive T1 signal
but at a lower sensitivity and greater likelihood of cell toxicity,
making it less suitable for biodistribution studies. None of these
MR methods can be directly correlated with cell number and thus
provide no quantiﬁable metrics of cell distribution. Perﬂuorocar-
bons yield signal that originates unequivocally from the labels and
that can be quantitated and directly correlated to the number of
cells in the tissue, but requires specialised coils and still suffers
from a relatively low sensitivity, particularly at clinical ﬁeld
strengths.17
Nuclear imaging makes use of radioactive probes to produce
images of physiological or functional signiﬁcance from within the
body.18, 19 There are two major nuclear imaging modalities used in
both preclinical and clinical practice: PET and SPECT. Cells directly
labelled with radionuclides such as Indium-111 (111In), Zirconium-
89 (89Zr), and Technetium-99m (99mTc) (see Box 2) or transduced
with nuclear reporter genes (see Box 3) can be tracked with very
high sensitivity; however the application of nuclear imaging is
limited due to the use of short-lived radioisotopes, and the
potential negative effects on the health of the therapeutic cells.20
Optoacoustic imaging is a relatively new imaging modality
which has become more commonly used in recent years.
Optoacoustic imaging relies on strong light absorbers, which
can be endogenous or exogenous molecules or probes (see Box 1,
Table 1). Endogenous biological contrasts include oxy-
haemoglobin and deoxy-haemoglobin, melanin, water, and
lipids,21 and are valuable for imaging vasculature, oxygenation
status, and tumours.22 However, it is the use of exogenous
contrast that is of particular interest to RMT applications. A
commercially available optoacoustic imager called ‘multispectral
optoacoustic tomography’ (MSOT) is capable of imaging at
multiple wavelengths.23 By detecting acoustic waves, MSOT is
able to overcome the scattering of emitted light which usually
limits the detection depth of many optical imaging methods, thus
permitting imaging depths of several centimetres, and allowing
the whole-body imaging of a mouse.24 Importantly, by illuminat-
ing tissues at multiple wavelengths, the signals from different
absorbers can be spectrally unmixed, allowing the differential
identiﬁcation of multiple absorbers at once. For cell tracking
purposes, cells can be labelled with probes that absorb within the
near-infrared (NIR), such as gold nanorods25 or carbon nanotubes
(see Box 2), or can be labelled with reporter genes encoding NIR
ﬂuorescent proteins (see Box 3). Moreover, optoacoustic imaging
can be performed in real time, allowing quantitative assessment of
organ function,26 thus enabling efﬁcacy studies in addition to cell
tracking. Even though this imaging technology is relatively new it
has recently been clinically used in oncology,27 human vascula-
ture28 and inﬂammatory response.29
Cell labelling
As indicated above, there are two broad categories of cell labels:
labelling probes and reporter genes. Labelling probes, also known
as direct labels, are required to be taken up by the cells (see Box 2,
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Fig. 1), whereas the use of reporter genes requires genetic
modiﬁcation of the cells (see Box 3, Fig. 1).
Probes used for cell labelling can produce a very strong signal
due to high cellular uptake30; however, they suffer from the
disadvantage that, when imaging, it is the probe, and not the cell
itself, which is being imaged.31 This presents a problem for false
positive results in cell tracking if the probe is released from the cell
of interest and taken up by host cells.32 Moreover, when cells
labelled with probes divide, the probes within the cell are
distributed between the daughter cells, resulting in signal
dilution.31 Therefore, when monitoring tumour growth, the probe
can no longer be detected following several cell divisions.
With the exception of luciferase enzymes, reporter genes (e.g.,
MR and optoacoustic reporters) tend to produce weaker signals
than imaging probes,33 with the limiting factors including
substrate biodistribution, background uptake and clearance,
and/or the expression levels of the reporter gene that can be
achieved in a given cell type.34 Moreover, some reporter genes,
such as the nuclear reporter gene HSV1-tk can generate an
immune response in the host, thus limiting the potential for long-
term imaging.35 The advantage of reporter genes, however, is that
the genetic modiﬁcation required to label the cells is passed onto
daughter cells during cell division, so that the signal intensity
increases as the cells proliferate, and signals are only lost when the
cells die.36
The ideal cell tracking agent should:
(I) be non-toxic to the cell and should not change the cell’s
phenotype, function, or differentiation potential;
(II) be easily taken up by the cell and should remain in the
desired location, either intracellular or membrane-bound;
(III) emit a strong signal for easy detection following adminis-
tration;
(IV) allow for quantiﬁcation of cell number;
(V) enable live and dead cells to be distinguished;
(VI) permit the identiﬁcation of the cell’s metabolic and
differentiation status. However, this is challenging and so
far has only been achieved using reporter genes under the
control of cell-speciﬁc promoters.37
Box 1 Imaging: how does it work?
Optical Imaging: Luminescence and Fluorescence
Optical imaging (i.e. bioluminescence or ﬂuorescence imaging) of cell-based RMTs involves the detection of emitted light from cells expressing an appropriate reporter gene
or labelled with a molecular probe.92 The reporter gene required for bioluminescence imaging encodes a luciferase enzyme which catalyses the oxidation of an exogenously
administered substrate, and results in the release of a photon.13 For ﬂuorescence imaging, light of a particular wavelength is emitted by ﬂuorescent molecular probes or by
ﬂuorescent proteins encoded by reporter genes following their excitation with a particular wavelength of light.92 The excitation and emission light can occur in the visible
part of the spectrum (400–700 nm) or in the near infrared (800–1900 nm),93 although the longer wavelengths are better suited for in vivo imaging due to the optical window
(see box 4). The detection of the light signal is performed by a cooled charge-coupled device (CCD) camera.93 The CCD is a photon detector that operates under a very low
temperature in order to eliminate any background noise, allowing a small number of photons to be detected,92 thus increasing sensitivity of detection.
Magnetic Resonance Imaging (MRI)
MRI uses a strong static magnetic ﬁeld to force the alignment of the spin moments of water protons in the subjects’ body relative to the magnetic ﬁeld. When a
radiofrequency (RF) pulse is applied, the spins are forced to a higher but unstable energy level. As soon as the radiofrequency pulse is turned off, these spins realign with the
main magnetic ﬁeld, releasing energy which is then detected by radiofrequency coils. The time taken to realign with the magnetic ﬁeld is called the spin-lattice, or T1
relaxation. At the same time, some energy is dissipated where the spins are dephased due to local magnetic ﬁeld inhomogeneities. The time taken for water protons to
dephase is called the spin–spin relaxation, or T2 relaxation. Different tissues exhibit speciﬁc T1/T2 relaxation times, which results in the characteristic contrast on greyscale
images after image reconstruction. This contrast in signal intensity allows differentiation between various normal and pathological tissues, and those containing contrast
agents, based on their spin relaxation properties94 Iron-based agents and reporters (SPIONs and reporters based on ferritin, transferrin or other genes related to iron
metabolism) reduce transverse (T2/T2
*) relaxation, leading to hypointense contrast (darkening) in the areas where the labelled cells are present. Paramagnetic-based agents
such as those based on gadolinium chelates shorten T1 relaxation, leading to positive (bright) signal in T1-weighted images. In perﬂuorocarbon-based imaging, the spin
alignment and relaxation processes described above apply to ﬂuorine atoms instead of water atoms. Because soft tissue is essentially absent from ﬂuorine, there is negligible
background and all signal is generated by the ﬂuorine-containing agent. A ﬂuorine coil is required, and images are usually overlaid with that of water proton imaging to
obtain an anatomical reference.
Positron emission tomography and single photon emission computed tomography Positron emission tomography (PET) or single photon emission computed
tomography (SPECT) are nuclear imaging modalities and utilize molecules containing radioactive atoms, which are structurally unstable and strive to achieve greater stability
by releasing energy/particles through radioactive decay. Different types of radiation with different frequencies and energy may be released from radionuclides, penetrating
short or long distances in the tissue.95 This ionizing energy is then detected by PET or SPECT detectors and the original location of the signal can be back-projected to
generate an image. PET tracers, such as ﬂuorine-18 or zirconium-89, emit small particles called positrons, which begin to lose kinetic energy after they have been produced,
until they eventually undergo a process called annihilation. This process involves the collision of positrons with nearby electrons within the body, and typically occurs within
1–2mm of the original site of decay, resulting in the release of two high energy photons, moving in opposite directions.96 These coincident photons are then measured by
collinearly aligned detectors, which provides the much higher sensitivity in PET imaging.97 In contrast, SPECT imaging uses one or more rotating gamma cameras in order to
detect gamma rays (photons), which are directly emitted by SPECT tracers such as indium-111 and technetium-99.98
Optoacoustic Imaging
A short pulse of non-ionising laser energy is applied to the sample, which can potentially absorb the energy and convert some of it into heat. The rise in temperature causes
thermoelastic expansion and subsequent relaxation, resulting in a spherical acoustic pressure wave which can be detected as an ultrasound wave. Different tissues of the
body will have different absorption, thermal, and elastic properties, and so the resulting ultrasound waves will reach the detector at different times and with different
amplitudes depending on the depth and characteristics of their tissue of origin. Contrast is driven by strong light absorbers—such as haemoglobin, melanin, and lipids—that
are naturally present in the body, and exogenous absorbers—such as gold nanorods, carbon nanotubes, some ﬂuorescent proteins, and some organic dyes—can potentially
be introduced to increase contrast. A optoacoustic image can then be generated by reconstructing the detected acoustic signals, using their magnitude and arrival times at
the detector to determine their location of origin.99 Optoacoustic detectors arrays come in two varieties: linear and tomographic. Linear arrays have the advantage of
comparative ease in adaptation of standard ultrasound imaging systems to include optoacoustic imaging, as ‘off-the-shelf’ linear array ultrasound transducers can be used in
combination with suitable lasers to generate optoacoustic images.100 Alternatively, tomographic arrays have also been developed for optoacoustic imaging.101 As compared
to linear array reconstruction, tomographic reconstructions produce more faithful images of anatomy since signals are detected from multiple angles. Scanning occurs by
translating the animal through the imaging plane 102 similar to MRI, PET and CT—which eliminates user variability induced by using a handheld device or approaches in
which a detector comes into direct contact with the skin. The disadvantage is the need to use custom-made transducers, which come at greater cost and are more complex.
As with traditional ultrasound imaging, optoacoustic imaging is performed with detectors that vary in centre frequency. Low frequency transducers (e.g., 1–10 MHz) allow
deeper tissue penetration (e.g., on the order of several centimetres) 103 but have characteristic lower spatial resolution (e.g., down to 80 um),104 while high frequency
transducers (e.g., 15–40 MHz) have limited tissue penetration (e.g., less than 1.0 cm) but greater spatial resolution.105
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If using ﬂuorescence or optoacoustic imaging, the label should
absorb light maximally within the NIR wavelength range (see
Box 4), as it is within this range that the absorption of endogenous
pigments, such as haemoglobin, melanin and fat are at a
minimum. This allows light to penetrate deeper into the tissue,
and signals from cell labels can be detected from deeper within
the animal’s body.
PRECLINICAL IMAGING APPROACHES TO EVALUATE CELL-
BASED RMTS
Cell biodistribution
It is essential to be able to track cells following their administration
and engraftment into the host, and imaging methods can be used
to answer some key questions regarding cell biodistribution. For
example, where do the cells go when they are administered,
particularly if they are administered systemically? Following
systemic injection, do the cells eventually reach the target organ,
and how long does it take them to do so? Do the cells integrate
within non-target organs? Alternatively, if the cells are adminis-
tered directly to the target organ, was the injection successful? Do
the cells stay within the target organ, or do they migrate
elsewhere over time?
Previously, these questions would have been answered by
sacriﬁcing multiple animals at several different time points and
detecting the transplanted cells via histological techniques.
However, by using imaging modalities, labelled cells can be
tracked over time in individual animals.38 Bioluminescence
imaging is one of the most useful modalities for monitoring cell
biodistribution, as whole body images of multiple animals can be
generated simultaneously in a matter of seconds, while detecting
as few as 10 cells.39 This modality can be used to monitor the
immediate biodistribution of cells following administration, and is
particularly useful for conﬁrming a successful injection,40 in
addition to tracking cell biodistribution over time (Fig. 2). Most
importantly, due to the requirement of an active ATP metabolism
for light production in cells expressing ﬁreﬂy luciferase, this
reporter provides a remote and highly-sensitive readout on
whether the cells are alive or not. Using bioluminescence imaging,
Table 1. Summary of the features of the four most commonly used imaging modalities in preclinical research
Imaging modality Features Cell tracking Other applications for regenerative
medicine
Optical Imaging: (Bio)
luminescence and
ﬂuorescence Imaging
(BLI; FLI)
Spatial resolution: 2–5mm
Temporal resolution: seconds to
minutes
Penetration depth:< 1 cm for
ﬂuorescence, 1–2 cm for
bioluminescence
Safety: completely safe
Cells transduced with reporter gene can
be tracked; the signal disappears with cell
death (no false-positives). Good for
tracking cell fate.
Tracking of biological processes and
molecular pathways such as cell
signalling.
Gene transfer efﬁciency in gene
therapy preclinical research.128
Tumour imaging.92,129
Cell differentiation.74
Semi-quantitative method. Output
measured in relative light units (RLUs),
which vary between different
luminometers.
Good cell tracking with ﬂuorescent
quantum dots, however signal weakens
with cell division and quantum dots from
dead cells can be phagocytosed by
macrophages and yield false positives—
not suitable for tracking cell fate.127
Alternatively, persistent luminescent
particles have excellent signal to noise
ratio, and reduced tendency to be
released from cells and so can be used to
track cells for longer periods of time than
most other optical probes.108
Magnetic resonance
imaging (MRI)
Spatial resolution: 40–100 um
Temporal resolution: minutes to
hours
Penetration depth: no limit
Safety: completely safe
Cells can be labelled with
superparamagnetic iron oxide
nanoparticles (SPIONs) or paramagnetic
metal chelates.
Oncology (tumour growth, perfusion,
ablation and oxygenation).131
Cardiology (heart perfusion).132
Musculoskeletal tissue structures.133
Magnetic reporters can also be used to
track cells, but lack sensitivity.55,130
Nuclear Imaging: PET and
SPECT
Spatial resolution: 1–2mm
Temporal resolution: seconds to
minutes
Penetration depth: unlimited
Safety: there are some safety
concerns over the use of radioactive
tracers, however doses are very low
and the risks are carefully monitored
Cells can be labelled with tracers for
short-term tracking, for example 111In
(SPECT) or 18F-Fluoro-Deoxyglucose (PET).
PET or SPECT provide high sensitivity,
which is an advantage for tracking
anatomical localization of stem cells
and nuclear imaging using reporter
genes permits long-term engraftment
studies.
SPECT and PET reporter gene imaging use
the principle of interactions between an
exogenous probe and the protein
produced by the reporter gene. There are
predominantly three genes: herpes
simplex virus type 1 thymidine kinase
(HSV1-tk), dopamine type 2 receptor
(D2R), and, sodium/iodide symporter
(NIS).97
Photoacoustic Imaging Spatial resolution: 20–300 μm
Temporal resolution: seconds to
minutes
Penetration depth: 4–5 cm
Safety: completely safe
Can image cells labelled with gold
nanorods30 or carbon nanotubes134, or
cells expressing NIR reporter genes.117
Can image down to 10,000 cells30 and can
quantify cell numbers.135
Excellent tumour imaging.22
Functional imaging of some organs/
tissues (using either endogenous or
exogenous contrast).136
Imaging of 3D scaffolds.81
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Yi Tang et al. tracked luciferase+ neural progenitor cells for up to
4 weeks as they migrated through the parenchyma of the brain
from the injection site into a brain tumour.38 However, a limit to
optical imaging is its depth limitation and poor spatial resolution13
and the fact that it is mostly restricted to 2D planar imaging. This
means that although the general biodistribution of cells can be
imaged, it can be difﬁcult to tell exactly which organ the cells are
located in, and it is not possible to monitor distribution within
speciﬁc organs. 3D optical imaging is possible,41 but it relies on a
pre-determined anatomical template, which may not accurately
match with the individual animal.
MRI and optoacoustic imaging are both able to provide much
higher spatial resolution,42, 43 and so can provide more detailed
information regarding cell location, and in some cases can also
allow for quantiﬁcation of approximate cell number. Nam et al.
used ultrasound-guided optoacoustic imaging to track mesench-
ymal stem cells (MSC) labelled with gold nanotracers for 1 week
following implantation.44 In vitro studies from this group
suggested that the amplitude of the optoacoustic signal was
directly related to the concentration of gold nanotracers, allowing
for reasonable conﬁdence in the quantiﬁcation of cell numbers
in vivo.44
Nuclear imaging, e.g., PET and SPECT, are highly sensitive
imaging modalities that can be used to track cell biodistribution
in vivo over the short-term and long-term, based on radionuclide
probe or genetic reporters, respectively. The PET probe, [18F]-2-
ﬂuoro-2-deoxy-D-glucose (18F-FDG), is a widely used biomarker of
cancer because it measures glucose metabolism, which is
increased in cancer cells. 18F-FDG can also be used to monitor
the immediate biodistribution of injected stem cells,45 but long-
Box 2 Cell labelling with probes
Many labelling techniques require cells to internalise probes, such as radio-
nuclides, nanoparticles, paramagnetic agents, or ﬂuorophores, which must then
remain intracellular. These molecular probes can then be tracked in vivo using
various different imaging techniques, depending on the probes used.
Commonly used agents for optical imaging are ﬂuorescent chemicals
(ﬂuorophores) including ﬂuorescent proteins,106 quantum dots (QDs),107 and
persistent luminescent nanoparticles.108 Optoacoustic imaging can also be used
to image cells labelled with ﬂuorophores. Paramagnetic agents, such as
superparamagnetic iron oxide nanoparticles (SPIONs)109 and gadolinium (Gd)-
based chelates,110 or perﬂuorocarbons (PFC),111 provide very good contrast
images for use in MRI. Radionuclides are radioactive cell labelling agents used to
track cells in vivo by positron emission tomography or single photon emission
computed tomography, depending on the type of radionuclide used. Commonly
used radionuclides include Indium-111 (111In), Zirconium-89 (89Zr) (Fig. 3),112 and
Technetium-99m (99mTc).31,113 Optoacoustic-speciﬁc agents include small
probes, such as gold nanoparticles and carbon nanotubes, which maximally
absorb within the NIR wavelength range.114 Gold nanoparticles come in a vast
range of morphologies, such as nanorods, nanotubes, nanostars, and nano-
spheres, and well-established synthesis procedures enable researchers to easily
modify the size and morphology of these gold nanoparticles, allowing their
optical properties to be tuned for speciﬁc applications.30,114
Most probe-labelling techniques have the advantage of producing an intense
signal which can be detected by the relevant imaging modality with greater
sensitivity than reporter genes, making them more effective for detecting low
numbers of cells. However, all labelling probes suffer from signal dilution that
occurs when the cell divides, and possible leakage of the probe from the cell of
interest, resulting in false positives. Labelling probes are therefore very good for
tracking cells in the short-term, but have limited potential for longer term cell
tracking or tracking rapidly proliferating cells.
Box 3 Cell labelling with reporter genes
Reporter gene labelling involves genetic modiﬁcation of cells to express reporter genes encoding reporter proteins, which generate imaging signals either constitutively,
after an enzymatic reaction, or after binding or transport of a substrate into the cell.
Reporter genes used in optical imaging generally include bioluminescent and ﬂuorescent reporter genes. Bioluminescent reporter genes encode a bioluminescent enzyme
called luciferase that releases light energy following a chemical reaction. The most common luciferases are ﬁreﬂy, renilla, click beetle, or gaussia.13,92 As light emission relies
on an enzymatic reaction, the animal must generally be administered the substrate to the enzyme prior to imaging, unless the enzyme and substrate are both expressed
constitutively, such as with the bacterial luciferase operon (lux),115 thus precluding the need for an exogenously administered substrate. Fluorescent reporter genes,
however, encode ﬂuorescent proteins that simply require an external light source to excite the ﬂuorophore92; therefore the administration of a substrate is not necessary.
Fluorescent proteins that maximally absorb within the ‘optical window’ (see box 4), such as Katushka2S,116 suffer minimal attenuation of signal due to low tissue absorbance
and are therefore more sensitive. Moreover, many ﬂuorescent reporter genes can also be detected by optoacoustic imaging,117 thus allowing for multi-modal imaging.
Reporter gene labelling methods used in MRI include reporter genes, such as tyrosinase,118 which result in T1 contrast following enzymatic reactions with their respective
substrates, yielding an increased signal. T2 or T2*-based MRI contrast is typically generated by reporter genes, such as the transferrin receptor or ferritin, whereby an increase
in the uptake or synthesis of iron or iron-bound proteins, results in a reduced T2 signal.
119
Radionuclide reporter genes are detectable by PET and SPECT imaging depending on the probe utilized. Sensitivity is highly reliant on the degree of accumulation and
retention of the tracer within the cell in concordance with rapid removal or wash out of unbound tracer to provide signal to noise. The herpes simplex virus type 1 thymidine
kinase (HSV1-tk) reporter gene is driven by a promoter/enhancer to express the reporter protein enzyme, thymidine kinase. Thymidine kinase phosphorylates exogenously
administered reporter probes, which remains restricted to the cytosol of the cell, resulting in highly speciﬁc and sensitive signals from labelled cells.120 Thus, radioactivity
reﬂects HSV1-tk enzyme activity and gene expression. However, different substrates for HSV1-tk such as the acyclguanosine derivitative (9-[4-[18F]ﬂuoro-3-(hydroxymethyl)
butyl]guanine ([18 F]FHBG) have been shown to accumulate in cells better than others.121 Nuclear reporters based on ligand binding, such as the Dopamine 2 receptor
(D2R)122 allows for one to one binding unless the receptor can be internalised. Thus, radioactivity reﬂects gene expression. However, this has limitations due to competitive
binding with native ligand, limited levels of expression due to competition of other membrane receptors, and also some ligand-binding strategies can initiate cell signalling
cascades that could lead to apoptosis or cell differentiation. Lastly, nuclear reporters based on transporter mechanisms such as the sodium-iodide symporter (NIS)123 or the
norepinephrine transporter (NET)124 actively transport or pump the tracer into the cell, allowing for increased accumulation and effective signal to noise. However, the NIS
system has a naturally high native expression in the thyroid and stomach, and also there is rapid efﬂux of the tracer from cells.
Nonetheless, reporter gene cell labelling techniques have important advantages over probes. In theory, signals generated from reporter genes are only generated from live
cells, and the agent producing the signal does not transfer from labelled cells to host cells, unlike with probe-based labelling methods. However, all nuclear reporter genes,
and some MRI reporter genes require the use of substrates, which in practice will produce background signals in parts of the body not containing reporter-expressing cells,
due to their incomplete clearance in normal tissue. The areas of background uptake are characteristic for each substrate, meaning that reporter gene selection for a speciﬁc
application can limit their use to areas with low background retention of the substrate. Importantly, and depending on the vector, due to their integration within the cell
genome, reporter genes are passed on to daughter cells, thus circumventing the signal dilution that occurs with direct labelling methods and allowing for the monitoring of
tumour development resulting from uncontrolled proliferation of cells. However, for longitudinal use, reporter gene techniques require cells to be stably transfected or virally
transduced in order to introduce the genetic label, which poses a risk of altering the cell phenotype and possibly inducing tumourigenicity or ablating regenerative potential.
The use of new genetic engineering techniques such as clustered regularly interspaced short palindromic repeats (CRISPR)/Cas that control the site of genetic modiﬁcation
can however reduce the risk of disrupting the coding sequences of native genes.125
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term tracking with 18F-FDG is not possible due to its short half-life
(110min). Cells can be tracked for up to a few days using isotopes
with longer half-lives, such as copper-64 (64Cu), 111In, and 89Zr,46, 47
but longer-term tracking requires the use of genetic reporters,
such as the HSVtk reporter that has been used to monitor the
biodistribution of progenitor cells for over 5 months in a porcine
model of myocardial injury.48 HSV1-tk has been the most widely
used nuclear reporter system to have been used in a range of
regenerative cell types in vivo,48 it is the only reporter gene to
have been clinically translated for the purpose of monitoring T cell
immunotherapies to cancer.49 As previously mentioned, immuno-
genicity of a non-human derived reporter protein has been a
problem for clinical translation. To overcome this limitation, a
human mitochondrial thymidine kinase type 2 (hTK2) has been
proposed.50 The further development of nuclear reporter systems
for regenerative cells has therefore been based on human derived
genes that have been previously worked up in other cell lines,
such as the as the D2R,51 and NIS52 systems. Although this
counters any immunogenicity concerns, the limitation is that there
is increased background uptake of the reporter probe natively
expressing tissues within the body. The sensitivity and resolution
is thereby dependent on the biodistribution of the reporter probe.
A shorter half-life is preferred for radionucleotide probes for
reporter systems as this allows for multiple imaging acquisitions
over a longitudinal time frame such as in the case of the HSVtk
reporter which has been used to monitor the biodistribution of
progenitor cells for over 5 months in a porcine model of
myocardial injury. Alternative approaches that involve the
systemic administration of cell targeting probes can also be used
to monitor cell biodistribution and/or provide information on cell
phenotype. For example, 64Cu (bound to arginine-glycine-aspartic
(RGD) tetramer conjugated with the macrocyclic chelator 1,4,7,10-
tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid (DOTA)) was
used to target αvβ3 integrin, in order to detect whether human
embryonic stem cells53 formed teratomas. However, a downside
to this approach is the lack of speciﬁcity.
Fig. 1 Diagram of the two classes of cell labelling methods, labelling probes and reporter genes, and examples of the labels used for each. a
Labelling cells with probes involves the uptake of exogenous probes e.g. SPION, 111In-oxine, QD, GNR, directly in to the cytoplasm of cells. b
Reporter gene labelling requires the introduction of foreign DNA into the cell’s DNA, to express a reporter protein. The reporter protein either
generates signal using endogenous substrates (e.g., ferritin), or it interacts with an exogenous substrate/detectable probe (e.g., luciferase,
HSV1-tk, human sodium iodide symporter (hNIS))
Box 4 The optical window
Biological tissues contain several different light-absorbing molecules, such as
haemoglobin, melanin, fat, and water, each of which absorb maximally at
characteristic wavelengths. Water and oxy-haemoglobin and deoxy-haemoglobin
are the major light absorbers in the tissues of animals, with the exception of
animals that exhibit black skin pigmentation, which also have strong absorption
by melanin. The 700–900 nm wavelength range is known as the ‘optical window’
or the ‘imaging window’ as it is in this region that water and haemoglobin have
their lowest absorption coefﬁcient (Fig. 4). Therefore, light can penetrate most
deeply within this wavelength range.126
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Dual-labelling of cells with both probes for short-term tracking
and reporter genes for long-term tracking might satisfy require-
ments for both highly sensitive immediate biodistribution, as well
as longitudinal tracking for tumour monitoring. For example, cells
could be transduced with luciferase for bioluminescence imaging,
providing high sensitivity but poor spatial resolution, and also
labelled with SPIONs for MR imaging, permitting the intra-organ
biodistribution to be evaluated with the excellent spatial
resolution of MRI (Fig. 5).
Alternatively, cells could be labelled with a single reporter gene
which allows for dual-modal imaging. Patrick et al. described a
reporter gene system based on the organic anion transporting
protein (Oatp1a1), which mediated the uptake of two contrast
agents for MRI and SPECT imaging, gadolinium- (Gd)
ethoxybenzyl-diethylenetriamine pentaacetic acid (EOB-DTPA)
and 111In-EOB-DTPA, respectively.54 Oatp1a1-expressing cells were
implanted in the ﬂanks of mice, and after systemic administration
of contrast agent, could be imaged longitudinally using both MRI
and SPECT, thus combining the advantages of both modalities: i.e.,
the high spatial resolution of MRI, and the sensitivity of SPECT.
Further, their sensitivity of detection with bioluminescence was
enhanced, due to Oatp1a1’s ability to increase uptake of the
substrate.55 Unlike labelling probes such as SPIONs or radio-
nuclides used to track cells with MRI and SPECT, this reporter gene
system can be used to monitor dividing cells over time, and does
not suffer from signal dilution.
Ngen et al. have described a dual contrast system comprised of
SPIONs and gadolinium chelates, which generate opposing
contrast signals and allow for the differentiation between live
and dead cells.56 When both contrast agents are present in live
cells, the strong T2 signal from the SPIONs quenches the T1
contrast from the gadolinium chelates. However, when cells die,
the gadolinium chelates are released and diffuse away from the
SPIONs, allowing the T1 signal to be detected in the region
surrounding the dead cells.56
When aiming to track cells over a long period, the cell label
should be chosen carefully. Some cell labels, while very sensitive,
cannot be detected after a certain period, due to either their
chemical degradation or radioactive decay. As a general rule,
labelling probes are unsuitable for long-term cell tracking, unless
Fig. 2 The absorption coefﬁcients of the main tissue absorbers,
water and oxy- and deoxy-haemoglobin, over 600–1100 nm. The
absorption of these endogenous pigments is at its lowest from
700–900 nm, creating an ‘optical window’ for in vivo imaging.
Reprinted with permission from Macmillan Publishers Ltd: Phan, T.
G. and Bullen, A. Practical intravital two-photon microscopy for
immunological research: faster, brighter, deeper. Immunology and
Cell Biology 88, 438–444, doi:10.1038/icb.2009.116 (2014)
Fig. 3 PET imaging shows the three dimensional biodistribution of
intravenously injected human adipose-derived stem cells labelled
with 89Zr-oxine. Bioluminescence imaging conﬁrms their viability
and the co-location of the cells and the radiotracer. Data generated
at the Centre for Advanced Biomedical Imaging (CABI), University
College London
Fig. 4 The absorption coefﬁcients of the main tissue absorbers,
water and oxy-haemoglobin and deoxy-haemoglobin, over
600–1100 nm. The absorption of these endogenous pigments is at
its lowest from 700–900 nm, creating an ‘optical window’ for in vivo
imaging. Reprinted with permission from Macmillan Publishers Ltd:
Phan, T. G. and Bullen, A. Practical intravital two-photon microscopy
for immunological research: faster, brighter, deeper. Immunology and
Cell Biology 88, 438–444, doi:10.1038/icb.2009.116 (2014)
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the cells are non-proliferating; for instance, it has previously been
shown that SPION-labelled neural progenitor cells can be tracked
in vivo for several weeks with MRI as these cells do not proliferate
following their differentiation.57
Tumourigenicity
A well-known safety concern of cell-based RMTs is the potential
for tumour formation by the engrafted cells.42 Stem cells have the
capacity for self-renewal and as such, may proliferate after
administration to form tumours.58 Pluripotent stem cells (PSCs)
pose a particular risk due to their tendency to form teratomas
and/or teratocarcinomas. However, with PSC-based therapies, it is
not the undifferentiated PSCs themselves that are administered,
but rather, their more differentiated derivatives; for instance, PSC-
derived retinal pigment epithelial cells are currently being tested
in the clinic for their potential to treat age-related macular
degeneration (ARMD).59 The main concern with such therapies is
the risk of tumour formation in the host by small numbers of
contaminating undifferentiated PSCs which might be present
within the administered population.
As it is difﬁcult to completely exclude this possibility, even when
using sensitive techniques such as quantitative PCR, it is important
to assess the risk of tumourigenicity in animal models prior to
commencing clinical trials. This is most easily done using
constitutively expressed reporter genes, because if integrated
into the genome, the reporter genes will be passed onto the
daughter cells when the original cells divide.36 Thus, if the cells
proliferate following transplantation, there will be an increase in
signal intensity, enabling tumour growth to be monitored
in vivo36 (Fig. 6).
In addition to the administered cells themselves forming
tumours, it is also possible that they could promote the growth
of endogenous tumours that are already present in the host; this
has previously been demonstrated following the administration of
MSCs into immune-compromised mice.60 Sensitive techniques are
required to detect such tumours, the most common being 18F-
FDG-PET, which can be used in both the preclinical and clinical
setting. Various approaches based on optoacoustic imaging are
also being developed, including enhanced haemoglobin contrast
that is a feature of highly vascularised tumours61 and uptake of
the NIR dye, indocyanine green, which passively accumulates in
tumours.62 Furthermore, speciﬁc tumour imaging can be achieved
by conjugating optoacoustic probes such as gold nanoparticles to
antibodies speciﬁc to particular cancer cell antigens.63
Immunogenicity
Cell-based RMTs derived from allogeneic sources have a high risk of
being immunogenic.64 Even autologous cells derived from the
patient have the potential to evoke an immune reaction when
transplanted back into the host, as in vitro culture conditions may
induce genetic, epigenetic, and phenotypic changes within the
cells.62,65 Prior to translating a cell therapy to the clinic, it is important
to try to determine the immunogenic potential of the human cells as
thoroughly as possible. This cannot be done using animal models
alone due to the inherent differences between animal and human
immune systems,61 and a combination of in vitro and in vivo studies
is required. Nevertheless, adoptive transfer and subsequent imaging
of immune cells may provide a means by which to monitor an
animal’s immune response to cell therapy over time.
A ﬂuorescent lipophilic dye, 1,1-dioctadecyltetramethyl indo-
tricarbocyanine iodide (DiR), has been used previously to label and
track adoptively transferred macrophages66 and T-lymphocytes,67
thus allowing imaging of the immune reaction by proxy of
exogenously administered cells. Eisenblätter et al. administered
DiR-labelled macrophages intravenously to a mouse model of
cutaneous granuloma, to non-invasively monitor the early
inﬂammatory response to subcutaneously implanted lipopolysac-
charide.66 This approach could be applied to image the
inﬂammatory response following the administration of an RMT.
Further, a range of ﬂuorescent probes can be directly adminis-
tered to animals to image sites of inﬂammation using ﬂuorescence
imaging.68 Haney et al. used the XenoLight RediJect Chemilumi-
nescent Probe, by Perkin Elmer, to image inﬂammation levels
following macrophage-mediated therapeutic drug delivery in a
mouse model of Parkinson’s disease.68 Alternatively, Faraj et al.
recently used MRI to non-invasively track SPION-labelled macro-
phages to sites of inﬂammation in a mouse model of chronic
obstructive pulmonary disorder.69
Fig. 5 Multi-modal imaging of Luciferase+/SPION+ stem cells administered to the left cardiac ventricle. a BLI gives a fast conﬁrmation of
successful IC injection, and gives an approximate location of cells, but lacks organ-speciﬁc information. b MR imaging of the kidneys before
and after the administration of SPION-labelled stem cells reveals that SPION-labelled cells are within the cortex of the kidney. Data generated
at the Centre for Preclinical Imaging, University of Liverpool
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Optoacoustic imaging can also be used to monitor the immune
response to administered cells. Ricles et al. labelled cells with both
gold nanorods and gold nanospheres, which have different
absorption spectra, thus allowing the two labels to be distin-
guished separately in vivo.70 The peak absorption of gold
nanospheres is changed when they are endocytosed by macro-
phages, allowing the differential identiﬁcation of signals coming
from live cells labelled with gold nanorods, and those coming from
endocytosed cells labelled with the now-visible gold nanospheres.
Using this method, Ricles et al. could monitor the viability of
administered therapeutic cells in vivo and the rate of tissue
macrophage inﬁltration over time. Additionally, by conjugating
gold nanorods to antibodies for inﬂammatory cytokines, inﬂam-
mation can be detected in vivo using optoacoustic imaging.71
However, for many reasons, we may not be able to fully
understand the immunogenic potential of cell therapies during
preclinical testing. Many products in preclinical research are
xenogeneic in the animal model, and differences in the animal
and human cellular product mean that the animal equivalent is
not fully predictive of the potential for immunogenicity in
humans. Moreover, for preclinical testing of a xenogeneic product,
the animals will either be immunocompromised or suppressed,
which is not necessarily the case in the clinical setting. None-
theless, preclinical imaging can aid in understanding aspects of
the interaction of the therapy with the immune system, and may
be able to inform the selection of RMTs with a lower potential for
immunogenicity.
Monitoring cell fate
An important aspect of monitoring the safety and efﬁcacy of RMTs
involves understanding the fate of the cells following administra-
tion. This is especially important for therapies based on progenitor
cells, where amelioration of disease requires the cells to
differentiate in vivo to one or more specialised cell types;
examples of such therapies include pluripotent stem cell (PSC)-
derived dopaminergic neuroblasts and PSC-derived oligodendro-
cyte precursor cells for the treatment of Parkinson’s disease72 and
multiple sclerosis,73 respectively. Differentiation status can be
assessed using cell-type-speciﬁc promoters to drive the expression
of a reporter gene. By combining a cell type-speciﬁc reporter with
a constitutively expressed reporter, it would be possible to
monitor the viability and biodistribution of all cells within the
administered population, and determine the proportion of cells
which undergo differentiation.
Recently, Ahn et al. demonstrated the use of a dual reporter
gene encoding both renilla and ﬁreﬂy luciferases, which can be
imaged independently using bioluminescence imaging.74 In
stably-transduced embryonic stem cells, the expression of renilla
luciferase was driven by the Oct4 promoter, and the expression of
ﬁreﬂy luciferase was driven by the ubiquitin promoter, allowing
the non-invasive monitoring of stem cell differentiation in vivo.74
Imaging can be a vital tool for monitoring the effect of
interventions to enhance the survival of administered cells in vivo.
Yang et al. used bioluminescence imaging to assess the survival of
adipose-derived stem cells (ADSCs) injected along the infarct
border in a rat model of myocardial infarction.75 Some rats were
administered ADSCs alone, while others were administered ADSCs
in combination with an injectable ﬁbrin scaffold to aid cell survival.
BLI at 4 weeks after cell transplantation showed that the addition
of the ﬁbrin scaffold signiﬁcantly improved the survival of
transplanted cells.75 3D biodegradable scaffolds are very impor-
tant in some RMTs, as they provide the therapeutic cells with the
structural support to proliferate and differentiate appropriately.
The scaffold is usually designed to break down after a certain
period of time, and it is important to be able to monitor the fate of
the scaffold over time. Nam et al. recently demonstrated the use
of multimodal imaging for monitoring and quantifying the
degradation process, in addition to monitoring the labelled
therapeutic cells that were seeded on the scaffold.76
Efﬁcacy of RMTs
In addition to monitoring cell biodistribution and fate, in vivo
imaging technologies allow the assessment of organ function, and
can therefore be used to monitor the efﬁcacy of RMTs. By imaging
organ function at baseline, after induction of injury, and after
therapeutic intervention, it is possible to monitor each individual
animal’s response to therapy. For instance, optoacoustic imaging
is excellent for monitoring organ function. The clearance of
exogenously administered dyes such as ICG and IRDye800
CW, which are speciﬁcally cleared through the liver26 and kidney77
(Fig. 7) respectively, allow assessment of organ function.
Optoacoustic imaging can also be used to assess oxygenation
status,78 brain function, such as resting state functional con-
nectivity,79 and angiogenesis.80
Fig. 6 BLI of Luciferase+ mouse kidney stem cells after intracardiac administration. BLI highlights the need for longitudinal imaging, as the
signal from cells can decrease initially as cells die, but tumours (arrows) may form at later time points. Data generated at the Centre for
Preclinical Imaging, University of Liverpool
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Experimental imaging studies can be designed to perform cell
tracking and efﬁcacy assessment in the same animal, and during
the same imaging session. Thus, individual responses to therapy
can be correlated with cell biodistribution and other cell tracking
data, such as proliferation and differentiation status, increasing the
amount of information gained from each animal. Recently, Nam
et al. demonstrated the value of optoacoustic imaging in
regenerative medicine to assess the severity of injury in a
cutaneous burn model, while simultaneously tracking gold
nanorod-labelled ADSCs.81
MRI can also be used to image organ function and tissue
regeneration. For example, Freeman et al. used MRI to assess the
efﬁcacy of MSCs administered directly into the intervertebral disc
in a study of degenerative disc disease in sheep.82 Using MRI, the
authors measured disc height and disc degeneration at multiple
time points, allowing the response to therapy for each individual
animal to be monitored over time. It is important to note that
apart from anatomical imaging, MRI offers a range of advanced
techniques that are currently used pre-clinically and clinically for
the evaluation of disease progression and response to therapies.
Those include, for example, diffusion weighted imaging, perfusion
imaging and MR spectroscopy, all of which are now well
established or under consideration for monitoring diseases of
the heart,83 liver,84 kidney 85 and brain86 and cartilage,87 among
others. Given the importance of these techniques, it is expected
that many of them will be also applied for the assessing RMT
efﬁcacy.
Mechanisms of action
It is not enough simply to know that a cell type is efﬁcacious in
treating a disease. Before clinical translation, it is important to
understand why the therapy appears to work, and its mechan-
ism of action. Do the cells need to integrate within the organ of
interest in order to have an effect? Do the cells even need
to be present in the organ of interest, or do they have
endocrine or paracrine effects which result in a resolution of
the disease? If cell-derived factors rather than the cells
themselves are responsible for promoting regeneration, then
these could potentially be isolated and used to develop a cell-
free therapy.
For instance, recent studies have shown that following
intravenous injection of MSCs88 or kidney-derived cells89 into
rodents with kidney disease, signiﬁcant therapeutic effects were
observed despite the fact that the cells were entrapped in the
lung and did not engraft in the kidney. Imaging can also be used
to optimise the ideal dosing conditions for maximum efﬁcacy of a
cell therapy, including the route of administration, number of cells
required per dose, and timing of dosing.40, 90
As released in guidelines from the European Medicines Agency,
the mechanism of action is also important to deﬁne a “potency
assay”, which should be used at the release of the ﬁnished product
before clinical application to show that the biological product will
be able to perform the intended clinical effect. This potency assay
should not only show that the cells are viable and can be
identiﬁed as e.g., MSCs, but also include a functional assay. The
assay demonstrating the biological activity should be based on
the intended biological effect which should ideally be related to
the clinical response.91
SUMMARY
Preclinical imaging is a valuable tool for the assessment of various
aspects of the safety and efﬁcacy of RMTs prior to clinical
translation. However, effective use of imaging technologies and
cell labels requires full understanding of their limitations, as well
as their potential. An important weakness to consider is the limit
of detection, with particular emphasis on the number of cells that
can realistically be detected with each modality/cell label
Fig. 7 Photoacoustic (multispectral optoacoustic tomography, MSOT) imaging of kidney clearance kinetics. a Temporal colour map indicates
the time it takes for a near infrared dye to clear through different regions of the kidney; cortex (C) and pelvis/papilla (P). b Quantiﬁcation of
the clearance kinetics of a NIR dye through the kidneys of control mice (CTRL) and mice with kidney injury (ADR), demonstrating that
photoacoustic imaging can be used to measure organ function. Reprinted under the Creative Commons CC-BY license from Scarfe et al.
Scientiﬁc Reports 5, doi: 10.1038/srep13601 (2015)
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combination. The key to successful use of imaging technologies is
understanding what is achievable and what is not, and full
acknowledgement of these limitations will enable the data that is
generated to be put into clinical context. This will allow the
consideration of subsequent alternative methods, such as tradi-
tional pathology assessment of the animals, or combination with
alternative, complementary imaging technologies.
Multimodal imaging is central to effective evaluation of RMT
safety and efﬁcacy. No single imaging modality is ideal; all are
associated with their own intrinsic strengths and weaknesses and
by combining two or more modalities, they can complement one
another to provide the maximum amount of information from a
single animal. Key to this is therefore dual- or triple-labelling of the
cells of interest for their visualisation by multiple imaging
modalities, thus gaining more information from each animal than
could be achieved with a single imaging modality.54, 56, 70 It is,
however, essential that adequate in vitro analyses are performed
prior to in vivo application, to ensure that all cell labels are
complementary with one another, and do not have adverse
effects on cell health or phenotype. Multimodal imaging
approaches to monitor cell biodistribution, cell fate, therapeutic
response etc., can vastly reduce the number of animals required
for RMT safety and efﬁcacy studies, as several different parameters
can be assessed longitudinally in the same group of animals,
without the need to sacriﬁce multiple animals at various time
points. Multimodal imaging therefore supports the principles of
the 3Rs (Reduction, Reﬁnement, Replacement) by reducing the
total number of animals required for such studies. Imaging
technologies are essential in the comprehension of the mechan-
isms of action and potential safety issues of RMT and thus will
allow a more accurate evaluation of the risk:beneﬁt ratio of these
therapies. These technologies will be essential (or a key player) to
move the RMT to clinical development.
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